HERTI 440MG

Product Description

• Active Ingredient: Trastuzumab (440 mg per vial).
• Mechanism of Action: It is a recombinant immunoglobulin G1 (IgG1) monoclonal antibody. It works by binding specifically to the HER2 receptors on the surface of cancer cells, which blocks the signals that promote cell growth and survival. This action inhibits the growth of cancer cells and can also make them more susceptible to destruction by the body's immune system.
• Uses:
  • HER2-positive breast cancer: Used in both early-stage and metastatic (spread to other parts of the body) conditions.
  • HER2-positive metastatic gastric (stomach) or gastroesophageal junction adenocarcinoma.
  • It can be used alone (monotherapy) or in combination with other chemotherapy agents, depending on the treatment plan prescribed by an oncologist.
• Administration: It is administered as an intravenous (IV) infusion by a healthcare professional in a hospital or clinic setting. The initial infusion is typically given slowly to monitor for any immediate reactions.
• Manufacturer: It is manufactured by Hetero Healthcare Ltd. in India.
• Storage: The injection typically needs to be stored in a refrigerator, between 2 to 8C (36 to 46F), and should not be frozen.